Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder
Authors:
Open Access
- 1 August 2017
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 74 (8) , 1010-1012
Abstract
In neuromyelitis optica spectrum disorder (NMOSD), enhanced plasma cell activity contributes to antiaquaporin-4 autoantibody (AQP4-ab) production.1 Longitudinal data indicate that 25% to 66% of patients with NMOSD who are treated with azathioprine, rituximab, and other immune-modifying therapies still experience relapses.2 Here we assess the safety and efficacy of bortezomib, a selective inhibitor of the 26S proteasome subunit, among patients with highly relapsing NMOSD.Keywords
This publication has 7 references indexed in Scilit:
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum DisordersJAMA Neurology, 2016
- Faculty Opinions recommendation of Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.2015
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015
- Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone MarrowImmunity, 2015
- Treatment of neuromyelitis optica: state-of-the-art and emerging therapiesNature Reviews Neurology, 2014
- Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis OpticaPLOS ONE, 2013
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritisNature Medicine, 2008